Liquid Biopsy Market size is set to grow by USD 1.74 billion from 2021 to 2026 | The Increasing incidence of cancer drives the market growth – Technavio

NEW YORK, Oct. 24, 2023 /PRNewswire/ — The liquid biopsy market size is estimated to grow by USD 1.74 billion from 2021 to 2026, according to Technavio. The market is estimated to grow at a CAGR of 18.77% during the forecast period. However, the growth momentum will be progressing. North America is estimated to account for 55% of global growth during the forecast period The increasing incidence of cancer is one of the major factors notably driving the growth of the liquid biopsy market. Globally, cancer is one of the leading causes of morbidity. The rapidly growing older population globally and at a high risk of getting cancer, due to the rise in average life expectancy. Moreover, end-users are increasingly preferring liquid biopsy over tissue biopsy as it is non-invasive and can detect the presence of different cancers more effectively using the individual’s blood sample. The growing incidence of cancers will subsequently increase the diagnosis using the liquid biopsy method, expected to drive the market growth during the forecast period. – Request a sample report

What’s New?

Special coverage on the Russia–Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession Global competitiveness and key competitor positions Market presence across multiple geographical footprints – Strong/Active/Niche/Trivial  – buy the report!

Liquid Biopsy Market – Segmentation Assessment
Segment Overview
Technavio has segmented the market based on technology (CTC and ctDNA and exosome and RNA) and geography (North America, Europe, Asia, and ROW). 

The liquid biopsy market share growth by the CTC and ctDNA segment will be significant during the forecast period.  The most preferred is the ctDNA test, as it is highly sensitive and allows analysis of DNA sequence and methylation. Furthermore, it permits timely and dynamic monitoring of tumor progression and can reduce the diagnosis bias from tumor heterogeneity. Vendors are mainly emphasizing the development of novel methods for capturing CTCs and ctDNAs to detect an extensive array of cancers before the physical manifestation of symptoms and to track the advancement of tumors throughout treatment. However, they are also working to explore ctDNA fluid biopsy to detect the emergence of resistant clones, which restrains the remission times achieved in patients treated with targeted therapies, and to correlate results from ctDNA with patient outcomes.

Geography Overview
By geography, the global liquid biopsy market is segmented into North America, Europe, Asia, and ROW. The report provides actionable insights and estimates the contribution of all regions to the growth of the global liquid biopsy market.

North America is estimated to account for 55% of global growth during the forecast period. In North America, The US and Canada are the key markets for liquid biopsy. The growing number of cancer cases, rising adoption of technologically advanced biopsy tests, increasing older population, high expenditure on the screening of types of cancers, and the increasing number of biotechnology and pharmaceutical companies driving the demand for anti-cancer drug development will facilitate the liquid biopsy market growth in North America during the forecast period.

Insights on the market contribution of various segments- Download a Sample Report

Liquid Biopsy Market – Market Dynamics

Leading trends influencing the market 

The increasing funding/investment for fluid biopsy is a liquid biopsy market trend that is expected to drive market growth. In the last few years, fluid biopsy gained momentum, both as a research tool and as sophisticated diagnostics technology. Thus, the market attracted investors to invest in the R&D of advanced technologies and the development and commercialization of fluid biopsy products. Multiple vendors, such as GRAIL, Guardant Health, Exosome Diagnostics, Pathway Genomics, and Inivata, received funding from various investors. Blood-based cancer detection firm Thrive Earlier Detection announced its launch, supported by USD110 million in funding in May 2019. Also, the firm announced plans to commercialize a circulating tumour DNA and protein testing method initially developed at Johns Hopkins University and undergoing validation in a 10,000-person trial with Pennsylvania’s Geisinger Health System. Therefore, such factors are expected to fuel the market during the forecast period.

Major challenges hindering the market growth

The major challenge for the liquid biopsy market is the limited reimbursement. Nowadays, there is only limited reimbursement and treatment monitoring for fluid biopsy, and it is performed in a few laboratories. However, reimbursement for fluid biopsy tests in oncology is not ensured even after approval, as it is still considered a novel and unproven technique. The criteria for reimbursement coverage include the type of cancer, the early or late screening procedure, and the type of therapy selected. Reimbursement for fluid biopsy is either low in developed countries or not available in a few countries. In developing countries, though there is a high market opportunity, technology is not much adopted. In countries such as China and India, a tissue biopsy is mostly preferred over a fluid biopsy. Lack of reimbursement and awareness about fluid biopsy can cause a decline in its adoption, which can impede the market growth.

Insights on Market Drivers, trends, & Challenges- Request a sample report!

What are the key data covered in this Liquid Biopsy Market report?

CAGR of the market during the forecast periodDetailed information on factors that will drive the growth of the liquid biopsy market between 2022 and 2026Precise estimation of the liquid biopsy market size and its contribution to the market in focus on the parent marketAccurate predictions about upcoming trends and changes in consumer behaviorGrowth of the liquid biopsy market across North America, Europe, Asia, and ROWA thorough analysis of the market’s competitive landscape and detailed information about vendorsComprehensive analysis of factors that will challenge the growth of liquid biopsy market vendors

Gain instant access to 17,000+ market research reports. 

Technavio’s SUBSCRIPTION platform

Related Reports:

The bone biopsy market is estimated to grow at a CAGR of 7.74% between 2022 and 2027. The size of the market is forecast to increase by USD 76.77 million. This report extensively covers market segmentation by type (needle biopsy and open biopsy), end-user (hospitals and diagnostic centers), and geography (North America, Europe, Asia, and the Rest Of the World (ROW)). The rising prevalence of cancer is notably driving the market growth.

The global breast biopsy devices market size is estimated to grow by USD 721.64 million between 2022 and 2027 accelerating at a CAGR of 10.95%. report extensively covers market segmentation by Product (biopsy needles and systems, biopsy /image-guided systems, and others), End-user (hospitals, ascs, breast cancer speciality centers and clinics, and others),  and Geography (North America, Europe, Asia, and Rest of World (ROW)). The demand for advanced breast biopsy devices has increased due to the rising adoption of minimally invasive procedures for breast cancer screening.

Table of contents

1 Executive Summary

2 Market Landscape

2.1 Market ecosystem Exhibit 01: Parent marketExhibit 02: Market characteristics2.2 Value chain analysis Exhibit 03: Value Chain Analysis: Healthcare supplies

3 Market Sizing

3.1 Market definition Exhibit 04: Offerings of vendors included in the market definition3.2 Market segment analysis Exhibit 05: Market segments3.3 Market size 2020 3.4 Market outlook: Forecast for 2020 – 2025Exhibit 06: Global – Market size and forecast 2020 – 2025 (USD million)Exhibit 07: Global market: Year-over-year growth 2020 – 2025 (%)

4 Five Forces Analysis

4.1 Five forces summary Exhibit 08: Five forces analysis 2020 & 20254.2 Bargaining power of buyers Exhibit 09: Bargaining power of buyers4.3 Bargaining power of suppliers Exhibit 10: Bargaining power of suppliers4.4 Threat of new entrants Exhibit 11: Threat of new entrants4.5 Threat of substitutes Exhibit 12: Threat of substitutes4.6 Threat of rivalry Exhibit 13: Threat of rivalry4.7 Market condition Exhibit 14: Market condition – Five forces 2020

5 Market Segmentation by Technology

5.1 Market segments Exhibit 15: Technology – Market share 2020-2025 (%)5.2 Comparison by Technology Exhibit 16: Comparison by Technology5.3 CTC and ctDNA – Market size and forecast 2020-2025Exhibit 17: CTC and ctDNA – Market size and forecast 2020-2025 (USD million)Exhibit 18: CTC and ctDNA – Year-over-year growth 2020-2025 (%)5.4 Exosome and RNA – Market size and forecast 2020-2025Exhibit 19: Exosome and RNA – Market size and forecast 2020-2025 (USD million)Exhibit 20: Exosome and RNA – Year-over-year growth 2020-2025 (%)5.5 Market opportunity by Technology Exhibit 21: Market opportunity by Technology

6 Customer landscape

7 Geographic Landscape

7.1 Geographic segmentation Exhibit 23: Market share by geography 2020-2025 (%)7.2 Geographic comparison Exhibit 24: Geographic comparison7.3 North America – Market size and forecast 2020-2025Exhibit 25: North America – Market size and forecast 2020-2025 (USD million)Exhibit 26: North America – Year-over-year growth 2020-2025 (%)7.4 Europe – Market size and forecast 2020-2025Exhibit 27: Europe – Market size and forecast 2020-2025 (USD million)Exhibit 28: Europe – Year-over-year growth 2020-2025 (%)7.5 Asia – Market size and forecast 2020-2025Exhibit 29: Asia – Market size and forecast 2020-2025 (USD million)Exhibit 30: Asia – Year-over-year growth 2020-2025 (%)7.6 ROW – Market size and forecast 2020-2025Exhibit 31: ROW – Market size and forecast 2020-2025 (USD million)Exhibit 32: ROW – Year-over-year growth 2020-2025 (%)7.7 Key leading countries Exhibit 33: Key leading countries7.8 Market opportunity by geography Exhibit 34: Market opportunity by geography (USD million)

8 Drivers, Challenges, and Trends

8.1 Market drivers 8.2 Market challenges Exhibit 35: Impact of drivers and challenges8.3 Market trends 

9 Vendor Landscape

9.1 Overview Exhibit 36: Vendor landscape9.2 Landscape disruption Exhibit 37: Landscape disruptionExhibit 38: Industry risks9.3 Competitive scenario 

10 Vendor Analysis

10.1 Vendors covered Exhibit 39: Vendors covered10.2 Market positioning of vendors Exhibit 40: Market positioning of vendors10.3 ANGLE Plc Exhibit 41: ANGLE Plc – OverviewExhibit 42: ANGLE Plc – Product and serviceExhibit 43: ANGLE Plc – Key offerings10.4 Bio Techne Corp. Exhibit 44: Bio Techne Corp. – OverviewExhibit 45: Bio Techne Corp. – Business segmentsExhibit 46: Bio Techne Corp. – Key newsExhibit 47: Bio Techne Corp. – Key offeringsExhibit 48: Bio Techne Corp. – Segment focus10.5 Biocept Inc. 10.6 CIRCULOGENE Exhibit 53: CIRCULOGENE – OverviewExhibit 54: CIRCULOGENE – Product and serviceExhibit 55: CIRCULOGENE – Key offerings10.7 F. Hoffmann-La Roche Ltd. Exhibit 56: F. Hoffmann-La Roche Ltd. – OverviewExhibit 57: F. Hoffmann-La Roche Ltd. – Business segmentsExhibit 58: F. Hoffmann-La Roche Ltd. – Key newsExhibit 59: F. Hoffmann-La Roche Ltd. – Key offeringsExhibit 60: F. Hoffmann-La Roche Ltd. – Segment focus10.8 Guardant Health Inc. Exhibit 61: Guardant Health Inc. – OverviewExhibit 62: Guardant Health Inc. – Business segmentsExhibit 63: Guardant Health Inc. – Key newsExhibit 64: Guardant Health Inc. – Key offerings10.9 LungLife AI Inc. Exhibit 65: LungLife AI Inc. – OverviewExhibit 66: LungLife AI Inc. – Product and serviceExhibit 67: LungLife AI Inc. – Key offerings10.10 Myriad Genetics Inc. Exhibit 68: Myriad Genetics Inc. – OverviewExhibit 69: Myriad Genetics Inc. – Business segmentsExhibit 70: Myriad Genetics Inc. – Key newsExhibit 71: Myriad Genetics Inc. – Key offeringsExhibit 72: Myriad Genetics Inc. – Segment focus10.11 QIAGEN NV Exhibit 73: QIAGEN NV – OverviewExhibit 74: QIAGEN NV – Business segmentsExhibit 75: QIAGEN NV– Key newsExhibit 76: QIAGEN NV – Key offeringsExhibit 77: QIAGEN NV – Segment focus10.12 SAGA Diagnostics AB Exhibit 78: SAGA Diagnostics AB – OverviewExhibit 79: SAGA Diagnostics AB – Product and serviceExhibit 80: SAGA Diagnostics AB – Key newsExhibit 81: SAGA Diagnostics AB – Key offerings

11 Appendix

11.1 Scope of the report 11.2 Currency conversion rates for USUSDExhibit 82: Currency conversion rates for USUSD11.3 Research methodology Exhibit 83: Research MethodologyExhibit 84: Validation techniques employed for market sizingExhibit 85: Information sources11.4 List of abbreviations Exhibit 86: List of abbreviations

About US
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/liquid-biopsy-market-size-is-set-to-grow-by-usd-1-74-billion-from-2021-to-2026–the-increasing-incidence-of-cancer-drives-the-market-growth—technavio-301965185.html

SOURCE Technavio